Bone Therapeutics raises €7.7m to progress PhIII PREOB, with plans for more
This article was originally published in Scrip
Belgian biopharmaceutical company Bone Therapeutics has closed a series D funding round raising €7.7 million, which the company will use to sustain its two Phase III trials with lead product PREOB.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.